ResMed Inc.
RMD
Rank in Stocks
#718
ResMed Inc. is a leading global medical technology enterprise engaged in the... ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
Share Price
$239.65
Last synced: 2026-10-19
Market Cap
$33.70B
Change (1 day)
0.49%
Change (1 year)
-11.70%
Country
US
Trade ResMed Inc. (RMD)
Category
Healthcare
P/E ratio for ResMed Inc. (RMD)
P/E ratio as of October 2026 TTM: 22.54
According to ResMed Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.54. At the end of 2024 the company had a P/E ratio of 26.92.
P/E ratio history for ResMed Inc. from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 22.54 | -16.59% |
| 2025 | 27.02 | 0.38% |
| 2024 | 26.92 | -24.65% |
| 2023 | 35.73 | -9.05% |
| 2022 | 39.28 | -47.96% |
| 2021 | 75.49 | 69.35% |
| 2020 | 44.58 | 1.83% |
| 2019 | 43.78 | -6.58% |
| 2018 | 46.86 | 45.70% |
| 2017 | 32.16 | 27.81% |
| 2016 | 25.16 | 12.14% |
| 2015 | 22.44 | 8.16% |
| 2014 | 20.75 | -0.27% |
| 2013 | 20.80 | 16.45% |
| 2012 | 17.86 | -14.08% |
| 2011 | 20.79 | -13.89% |
| 2010 | 24.14 | 14.81% |
| 2009 | 21.03 | -16.13% |
| 2008 | 25.07 | -47.48% |
| 2007 | 47.74 | 24.01% |
| 2006 | 38.49 | 10.09% |
| 2005 | 34.97 | 16.65% |
| 2004 | 29.97 | 5.79% |
| 2003 | 28.33 | 18.64% |
| 2002 | 23.88 | -82.35% |
| 2001 | 135.33 | 272.77% |
| 2000 | 36.30 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 33.11 | 46.91% |
US
|
|
| 21.39 | -5.10% |
IE
|
|
| 28.94 | 28.43% |
US
|
|
| 17.34 | -23.07% |
US
|
|
| - | - |
DE
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.